The University of South Florida along with Moffitt Cancer Center has published a study in the October issue of Brain, Behavior, and Immunity which found that men with advanced prostate cancer who are on androgen deprivation therapy (ADT) are more likely to suffer from general fatigue if they also have single nucleotide polymorphisms in three [...]
According to a study published online May 9 in The American Journal of Pathology copy number variations (CNV) in both malignant and benign prostate tissue is predictive of prostate cancer relapse. The research performed at the University of Pittsburgh School of Medicine by Yan P. Yu, M.D. and colleagues evaluated whether CNV of the genomes [...]
We know that both a positive family history and racial background are among the strongest epidemiological risk factors for prostate cancer. It is also recognized that the role of candidate genetic markers to prostate cancer is more difficult to identify than the identification of other cancer susceptibility genes. Despite the localization of several susceptibility loci, [...]
In today's issue of Cancer Discovery a group of international researchers report that an investigational drug had a dramatic response in animal models of neuroendocrine prostate cancer, a lethal form of the disease. The researchers pointed out that fewer than 2% of prostate tumors in men are initially diagnosed as neuroendocrine, but many of the [...]
According to research published today in the British Journal of Cancer, routine testing for a faulty BRCA2 gene (Kote-Jarai Z et al, BRCA2 is a gene contributing to young onset prostate cancer: implications for genetic testing in prostate cancer patients British Journal of Cancer (2011) doi:10.1038/bjc.2011.383) in men under 65 years with prostate cancer could [...]